TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sexual Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Health & Well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intraclass correlation between LI-IUS scores and LI-MRE scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Self-reported 7-day point-prevalence abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of grade 3 or higher gastrointestinal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Thermal sensory threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrical pain sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thermal pain tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cold immersion pain tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain wind-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in MAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in ASD Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improvement in negative emotional states
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of severe acute GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of LY3454738
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) of LY3454738
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point prevalence tobacco abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of favorable functional outcome at 90-day
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Area under the Receiver Operating Characteristic curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1C Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Newborn Physical Assessment Skills Control List (NPA-SCL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Newborn Physical Assessment Knowledge Test (NPA-KT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: detection rate at the patient level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection rate at the lesion level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of decrease in epileptic seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with refractory urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Impact of urinary artificial sphincter on the participants' incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Participants who Achieve Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants who Achieve Psoriasis Scalp Severity Index (PSSI) 90 Response at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants who Achieve Scalp-specific Investigator Global Assessment (ss-IGA) Score of Absence of Disease (0) or Very Mild Disease (1) at Week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of LIBP-Rec-Vaccine/BIBP-Rec-Vaccine against COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Breastfeeding intention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of MRI-QSM of the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of MRI-QSM of the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of MRI-QSM of the liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Atopic Dermatitis Severity score (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Atopic Dermatitis Severity score (Investigator's Global Assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biochemical parameters (TAS sample)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biochemical parameters (TOS sample)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete clearance of BCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to Return to Baseline Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence time of acute and chronic radiation rectal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Complete Response rate at 30 months (CR30)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to First Occurrence of Composite Heart Failure Endpoint
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of distal radial artery occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in coping with stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1 (28 days)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of self-reported overdose risk behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve from time 0 to the last measurable concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve from time 0 extrapolated to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family function outcomes
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Incidence of long COVID
Endpoint domain: Mortality/survival
Primary endpoint: DLTs incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Symptoms post anti-COVID-19 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of pediatric patients with access to remote monitoring
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in serum potassium levels from baseline to Day 540±7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in systolic blood pressure (SBP) from baseline to Day 540±7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of days alive and at home following surgery
Endpoint domain: Mortality/survival
Primary endpoint: GMT of anti SARS-CoV-2 specific neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Microbiota composition of breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metric and Drug Dose Calculation Knowledge Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Facial Blemishes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence rate of Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy and precision of blood pressure monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dim Light Melatonin Onset (DLMO) phase shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep restriction dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Emotional symptom cluster
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Range of motion at hip joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability related to back pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient tolerance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in mobility scores from admission to discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fidelity of PREVENT tool implementation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes in mean deviation (MD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pattern standard deviation (PSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in visual field index (VFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mass balance recovery of total radioactivity in urine and fecal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total radioactivity in plasma PK: AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic blood pressure drop correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Map of organ-specific functional activity in the cervical vagus nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biphasic Effects of Alcohol (BAES)--Stimulation Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biphasic Effects of Alcohol--Sedation Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early feeding skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total intravenous (IV) and oral narcotic analgesic use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Variation in sleep quality
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: early diagnosis for assessing kidney function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Signal Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Retinal Fluid (TRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-Retinal Fluid (IRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sub-Retinal Fluid (SRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cough-Related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline Hygiene Index at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Index of Gingival Bleeding at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immune-related adverse events (irAE)
Endpoint domain: Adverse events/effects
Primary endpoint: occurrence rate of anastomotic stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: occurrence rate of reflux esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and Tolerability as Measured by Number of Participants That Experienced Other Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and Tolerability as Measured by Number of Participants That Experienced Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of clinically relevant changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of clinically relevant changes in electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dental effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in the incidence of Treatment-Emergent Adverse Events with supplementation as assessed by renal (kidney) function
Endpoint domain: Adverse events/effects
Primary endpoint: Morphine mEqs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic value of ctDNA testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute and long-term follow-up success rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of intraoperative and long-term serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Dynamic Compliance assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak inspiratory pressure assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevention methods used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline in 6 minute walk test (6MWT) total distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of matching drug allergy testing and drug allergy labels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent reduction in daily maintenance OCS dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient/family interest
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: technical ease-of-use and satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Complex Technical Completion Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complex Technical Completion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complex Tactics Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of antibiotics prescribed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HIV Testing Related Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: HIV Related Stigma
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: change in Blood pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pittsburgh Sleep Quality Index score (PSQI S)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Time to HLH diagnosis from the initial presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Unbound Plasma Concentration-time Curve from Time Zero to t (AUC0-t,u) of Emraclidine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence-Free survival
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of forced vital capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Average number of CAE sessions attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of subjects that agree the intervention was useful
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Experience Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: First successful extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Muscle activation ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of participants prescribed appropriate treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Geometric mean titer (GMT) ratio of antibodies after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety Profile Measured by Grade ≥3 TRAE
Endpoint domain: Adverse events/effects
Primary endpoint: Area under receiver operating characteristic (ROC) curve of the microRNA signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate of the target nail
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urine albumin-creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Emotion Dysregulation Inventory scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PrEP uptake at 12 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HIV virologic suppression at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days of past-28-day non-tobacco drug/alcohol use
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change from baseline in Body mass index-BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy expenditure in ml of oxygen consumed per minute per kg of body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Palatal wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in magnitude of IL-2 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of Life Scale During Pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Psychometric Properties of Eurohis (Whoqol-8.Tr) Turkish Version in Turkish Society
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Premenstrual Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Performance of rapid diagnostic tool (UB-CAM) for acute confusional state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic Pain Impact Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Constipation Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Concentration (AUC 72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in NDI score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vitamin B12 bound to transcobalamin II (holoTc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total B12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in scores of the house Brackman grading system HB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in scores of the Sunnybrook grading system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tPASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Relative change in alanine aminotransferase (ALT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Changes on psychological well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Generalized Anxiety Disorder-7 (GAD-7) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Korean version of the Perceived Stress Scale (K-PSS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Brief Diabetes Distress Screening Instrument (DDS-2) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in European Quality of Life-5 Dimensions 3 Level (EQ-5D-3L) index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Frequency of documented vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transaortic valve gradients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transaortic mean gradient reclassification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VARC-3 hemodynamic valve deterioration reclassification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient-Prosthesis Mismatch (PPM) reclassification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gut mycobiome compositional signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gut mycobiome biomarkers identification for early detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health beneficial Gut Mycobiome identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In vivo adipogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hospital free survival
Endpoint domain: Mortality/survival